Clinical Trials Browser

OTHER × Lymphoma, Non-Hodgkin × obinutuzumab × Clear all

NCT03198026 2026-02-19

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Phase 2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT02393157 2025-08-08

O-ICE

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03401853 2025-07-22

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Phase 2 Terminated

18 enrolled 14 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT03311126 2024-10-24

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Phase 2 Terminated

21 enrolled 17 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02877550 2022-06-10

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Phase 1 Completed

Lymphoma, Follicular, Lymphoma, Non-Hodgkin